Ionis hands off an antisense drug for kidney disease, giving all rights to Roche

Ionis announced early Monday that Roche is in-licensing and advancing the antisense drug candidate known as IONIS-FB-LRx into a Phase III clinical study. The drug is being investigated for immunoglobulin A nephropathy (IgAN), a kidney disease that can lead to renal failure. The disease is marked by immunoglobulin A buildup in the kidneys, resulting in inflammation and ultimately kidney failure if left untreated.